BIRC2 blockade facilitates immunotherapy of hepatocellular carcinoma

Table 4 Cox proportional hazards model analysis of prognostic factors in HCC patients who have received anti-PD-1 plus lenvatinib therapy

	HR	95% CI	Unfavorable/Favorable	P
Univariate analysis
BIRC2	5.812	1.215–2.802	High/low	0.028
Gender	1.079	0.229–5.087	Male/female	0.924
NIK	1.763	0.567–3.338	Low/high	0.582
HLA-ABC	1.931	0.499–7.470	Low/high	0.341
PD-L1	1.012	0.211–5.024	High/low	0.721
Age	1.129	0.318–4.005	≥ 49/<49	0.851
Vascular invasion	2.152	0.623–7.438	Present/absent	0.226

ISSN: 1476-4598